x
Novalis VC
Novalis Biotech is an early stage venture capital investor in life sciences. We welcome innovative concepts in TechBio and aim to support their development already at the state of incorporation. Our investment focus is “enabling technologies” in life sciences. We strongly believe in capital light platform technology and close interaction with customers already early in the life of the company. Focus areas are: innovative research and manufacturing tools, bioinformatics, genomics, diagnostics and digital health. We focus on early-stage start-ups, from (pre-)seed stage to series A, and support their evolution by providing funding, sharing our professional and academic connections, and helping to shape the business strategy in order to create value for all stakeholders.
New York Ventures
New York Ventures, a division of Empire State Development, is an early-stage venture capital fund that invests in high growth start-up companies across all regions of New York State. We administer the state’s innovation investment funds by partnering with entrepreneurs to build the future of New York, prioritizing companies that solve important challenges in the areas of life sciences, climate tech, agriculture, information sciences and other emerging technologies. New York Ventures is actively deploying over $300 million of capital through equity programs for both direct and indirect investment.
Linearis
Linearis is transforming healthcare by merging artificial intelligence and biomarker analysis to enhance patient care with more precise, accessible prevention, detection, treatment of metabolic diseases including cancer, diabetes, and antimicrobial resistance. The team unites unparalleled, world-renowned experts in biomarker discovery, drug development, biopharma, and healthcare innovation. Alexandre Le Bouthillier, a serial AI entrepreneur and CEO, collaborates with Jacques Corbeil, holder of the Canada Research Chair in Medical Genomics and CSO, and Manon Boisclair, a global biopharma executive and COO/CCO. Together, they have discovered and internationally marketed medical diagnostics and treatments. Contributions from Yoshua Bengio, a co-father of modern AI and Turing Prize winner, David Wishart, curator of the Human Metabolome Database, bolster Linearis’ efforts in providing the first certified industrial laboratory that combines high-throughput metabolomic analysis and AI. | Linearis with its tandem Ventures Fund and Laboratory is pioneering and supporting discoveries to prevent, detect, and cure metabolomic diseases including cancer & diabetes through direct investments in innovative AI-powered life sciences companies. Linearis Ventures leverage its AI and multi-omics expertise to support life science companies’ growth, accelerating their trailblazing innovation and advancing biomarkers to provide critical insights into a broad spectrum of health conditions. Linearis Labs provide services to large biobanks, CROs and BioPharma companies across their life cycle management from drug discovery, patient screening, disease prevention as well as treatment monitoring.
Life Sciences Greenhouse Investments
A public/private evergreen venture fund that invests in early-stage life science companies with substantive ties to Pennsylvania, USA. • Average Ticket: initial investment of $250,000 – $500,000 ; follow-on funding of $1-2M • Investment Stage: seed through Series A for initial investment • Sector: human health, including novel therapeutics; medical devices; diagnostics; clinical-facing IT; and tools that facilitate discovery, R&D, and scale-up. Will consider ag-tech and animal health technologies with the potential to impact human health
Kiva Capital Group
Kiva Capital is a purpose-driven investment and development firm that funds and structures large-scale initiatives delivering measurable commercial and societal outcomes. From sovereign cloud networks to sustainable housing and next-generation communities, we orchestrate capital around ideas that matter.
Jackpot Digital Inc.
Bring sizzle to your casino floor with the incredible dealerless Jackpot Blitz poker table! Come and play our stunning 75″ touchscreen multiplayer table, ‘bend’ the cards right onscreen, and play engaging side bets and mini games such as BET THE FLOP, Blackjack, Baccarat and Video Poker!
IntelliCasino AI
IntelliCasino AI is a tribally owned and operated team of enrolled data scientists, guided by a tribal casino founder with decades of experience in the gaming industry. We offer a unique blend of cultural integrity and cutting-edge AI innovation, tailor-made to help tribally owned casinos enhance player engagement, optimize operations, and achieve sustainable revenue growth. Our core philosophy centers on respecting Tribal values and sovereignty: we ensure that every AI-driven recommendation, system integration, or data-analytics project preserves our heritage while delivering cutting-edge results. We believe that combining deep tribal community insights with leading technologies like machine learning, predictive analytics, and AI-powered monitoring creates a powerful synergy that allows casinos to stand out in an increasingly competitive market. One of our hallmark solutions is our AI-Enhanced Player Engagement Tool, which uses advanced analytics to predict player preferences, offer personalized experiences, and deliver promotions in real time. By integrating this tool with casino management systems, we’ve seen remarkable improvements in player retention and satisfaction. Additionally, our Turtle Shield Suite offers real-time compliance monitoring, safeguarding data sovereignty, and ensuring tribal regulations are always upheld. Because we are tribally led, we understand the nuance of building trust and honoring cultural considerations in the gaming sphere. Our approach goes beyond standard business objectives: we work hand-in-hand with Tribal councils, decision-makers, and on-site gaming teams to co-create solutions that reflect each community’s distinct needs. By forging these close partnerships, we can design AI systems that amplify cultural storytelling, create welcoming gaming environments, and foster brand loyalty among patrons. We also offer comprehensive workforce optimization tools, such as automated scheduling that balances staff coverage with employee well-being, and customer journey tracking to identify key engagement points. This holistic understanding of both player and workforce experiences has enabled us to pinpoint new opportunities for growth, increase operational efficiency, and ensure a smooth, profitable casino operation. Ultimately, IntelliCasino AI strives to empower Tribal casinos to compete at the highest levels of the industry—without compromising on cultural values or data sovereignty. By harmonizing tradition and technology, we’re paving the way for a future where tribally owned casinos can celebrate their heritage, delight their players, and drive sustained success for generations to come. Feel free to connect with us to discover how our AI-driven solutions can transform your casino’s operations and elevate the player experience.
INSUD
Insud (Innovation, Sustainability and Development) is a business ecosystem with global reach that develops innovative solutions with a sustainability commitment to help improve fundamental aspects of human life: health, food and nutrition, energy and culture. In the pharmaceutical/biotechnology field, it operates throughout the value chain, providing its specialized knowledge in scientific research, development, manufacturing, sales and marketing of a wide range of products for human health. Insud Argentina stands out by developing monoclonal antibodies, vaccines and polyclonal immunotherapeutic sera. Nowadays we are developing alternative proteins, together with biotech startups. | Insud is a highly diversified group with global presence that operates across the entire pharmaceutical/biotech value chain, delivering specialized expertise in scientific research, development, manufacturing, sales and marketing of a wide range of compounds for human care. Insud Argentina stands out by developing monoclonal antibodies, vaccines and immunotherapeutic polyclonal sera.
IBEX Therapeutics SA
Ibex Therapeutics is Swiss biotech company developing a patented oral topical therapy to cure and prevent oral mucositis and oral candidiasis, debilitating conditions which very often occur as adverse effect of cancer chemo- and radiotherapy and affects the care journey and the quality of life of cancer patients. A de-risked and short path to registration and commercialization by 2028, as validated by the German health authority BfArM: the lead product (containing 2 water-based plant extracts) is produced in GMP conditions and has confirmed its efficacy and safety in a pilot study in cancer patients. Ibex Tx is raising CHF 3 million, of which 1.0+ million has already received soft commitments, with the largest part of the proceeds to fund a final pivotal clinical study, and some portfolio extensions (including a probiotic to synergize with the oral topical therapy, and a spray presentation to augment portability and convenience of use by ambulatory patients). Strong market fundamentals: sustained medical need (increasing incidence of cancer and use of mucositis-inducing therapies), and absence of reference treatment. Further, Ibex Tx will register the product in several geographies (EU, USA, Asia, BRICS), and sign licensing agreements to ensure efficient commercialization outside of Switzerland.